SAN ANTONIO, July 19, 2017 -- bioAffinity Technologies, a privately held company advancing early-stage cancer diagnostics and precision therapeutics, announced today that it raised more than $4 million in the recently closed Series A funding.
bioAffinity Technologies is commercializing a non-invasive, early-stage lung cancer test called CyPath® Lung that detects the disease when it can be successfully treated. CyPath® is a platform technology that will be expanded beyond lung cancer to diagnose multiple cancers, including prostate and cervical. OncoSelect Therapeutics, the Company’s drug development division, focuses on commercialization of targeted therapies to treat cancer.
“We remain focused on the development of safer, more effective cancer diagnostics including CyPath® Lung, a patient-friendly test to detect lung cancer at its earliest stages when treatment is most effective,” said bioAffinity President and CEO Maria Zannes. “Series A investments will propel our lung cancer diagnostic to commercialization and further our development of additional cancer tests and novel therapeutics that will treat cancer more effectively.”
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories and at UT Health at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747